CNS Pharmaceuticals, Inc. (CNSP) — Financial statements
Income statement, balance sheet, and cash flow for CNS Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00↓100.0% | 0.00↓20.0% | 0.00↓64.8% | 0.01↓10.1% | 0.01 | |
| Gross Profit | 0.00↑100.0% | -0.00↑20.0% | -0.00↑64.8% | -0.01↑10.1% | -0.01 | |
| Operating Expenses | ||||||
| R&D Expenses | 10↑5.2% | 9↓34.1% | 14↑51.6% | 9↓5.2% | 10 | |
| General & Administrative Expenses | 6 | 0.00↓100.0% | 5 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 6↑10.8% | 6↑17.6% | 5↓15.2% | 6↑20.4% | 5 | |
| Other Expenses | 0.00 | 0.00↑100.0% | -0.00 | 0.00 | 0.00 | |
| Operating Expenses | 16↑7.3% | 15↓21.0% | 19↑26.4% | 15↑3.1% | 14 | |
| Total Costs & Expenses | 16↑7.3% | 15↓21.0% | 19↑26.3% | 15↑3.1% | 14 | |
| Operating Results | ||||||
| Operating Income | -16↓7.3% | -15↑21.0% | -19↓26.3% | -15↓3.1% | -14 | |
| Depreciation & Amortization | 0.00↑18.5% | 0.00↓20.0% | 0.00↓64.8% | 0.01↓10.1% | 0.01 | |
| EBITDA | -16↓6.7% | -15↑21.3% | -19↓23.6% | -15↓5.4% | -14 | |
| EBIT | -16↓6.7% | -15↑21.3% | -19↓23.6% | -15↓5.4% | -14 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.14↑213.9% | 0.04↑218.0% | 0.01↑297.6% | -0.01↑24.2% | -0.01 | |
| Interest Income | 0.15↑155.2% | 0.06↑117.7% | 0.03↑394301.7% | 0.00↓24.4% | 0.00 | |
| Interest Expense | 0.02↓5.5% | 0.02↑16.8% | 0.01↑96.5% | 0.01↓24.3% | 0.01 | |
| Non-Operating Income | -0.15↓150.9% | -0.06 | 0.00↓100.0% | 0.33 | 0.00 | |
| Other Income / Expenses | 0.14↑208.1% | 0.04↑218.0% | 0.01↑104.1% | -0.34↓3574.4% | -0.01 | |
| Income Before Tax | -16↓6.7% | -15↑21.2% | -19↓23.4% | -15↓5.4% | -14 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -16↓6.7% | -15↑21.2% | -19↓23.4% | -15↓5.4% | -14 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -16↓6.7% | -15↑21.2% | -19↓23.4% | -15↓5.4% | -14 | |
| Bottom-Line Net Income | -16↓6.7% | -15↑21.2% | -19↓23.4% | -15↓5.4% | -14 | |
| EPS (Basic) | -35.75↑92.3% | -466.44↑99.7% | -150,114.00↑55.4% | -336,499.00↑32.0% | -495,027.00 | |
| EPS (Diluted) | -35.75↑92.3% | -466.44↑99.7% | -150,114.00↑55.4% | -336,499.00↑32.0% | -495,027.00 | |
| Weighted Average Shares | 0.44↑1291.9% | 0.03↑25382.4% | 0.00↑177.8% | 0.00↑55.2% | 0.00 | |
| Weighted Average Diluted Shares | 0.44↑1291.9% | 0.03↑25382.4% | 0.00↑177.8% | 0.00↑55.2% | 0.00 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.